31,249 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by Value Star Asset Management Hong Kong Ltd

Value Star Asset Management Hong Kong Ltd purchased a new stake in Moderna, Inc. (NASDAQ:MRNA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 31,249 shares of the company’s stock, valued at approximately $3,107,000. Moderna accounts for 1.1% of Value Star Asset Management Hong Kong Ltd’s portfolio, making the stock its 12th largest position.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company lifted its holdings in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares during the last quarter. Invesco Ltd. boosted its position in shares of Moderna by 19.8% in the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after acquiring an additional 517,683 shares during the period. Wellington Management Group LLP grew its stake in shares of Moderna by 9.3% in the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after acquiring an additional 476,201 shares in the last quarter. Bamco Inc. NY grew its stake in shares of Moderna by 4,863.6% in the third quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock valued at $44,091,000 after acquiring an additional 418,269 shares in the last quarter. Finally, abrdn plc raised its stake in Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock worth $48,091,000 after purchasing an additional 399,843 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the transaction, the insider now owns 9,267 shares in the company, valued at approximately $917,896.35. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $108.32, for a total transaction of $1,624,800.00. Following the completion of the sale, the director now owns 2,041,931 shares in the company, valued at $221,181,965.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Shannon Thyme Klinger sold 544 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $99.05, for a total transaction of $53,883.20. Following the completion of the transaction, the insider now owns 9,267 shares in the company, valued at $917,896.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,954 shares of company stock valued at $13,158,776. Corporate insiders own 15.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. William Blair reiterated a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Canaccord Genuity Group boosted their price target on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. HSBC reissued a “reduce” rating and issued a $86.00 price target (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $126.49.

Moderna Stock Up 1.0 %

Shares of MRNA stock traded up $1.15 during trading hours on Wednesday, reaching $111.46. The company had a trading volume of 3,814,197 shares, compared to its average volume of 4,046,325. The business has a fifty day simple moving average of $103.47 and a 200-day simple moving average of $93.79. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79. The company has a market cap of $42.68 billion, a price-to-earnings ratio of -8.89 and a beta of 1.62. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. The firm had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The business’s revenue for the quarter was down 44.9% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.61 EPS. On average, research analysts expect that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.